The real-life outcome of pazopanib in patients with advanced soft tissue sarcoma: A retrospective cross-sectional study of a Turkish cohort.

Mustafa Karaağaç Yasin Sezgin Melek Karakurt EryilmazMurat ArazMuhammet Ali KaplanMustafa Yıldırım

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)

We showed that pazopanib was well tolerated and had clinical benefit in patients with advanced soft tissue sarcoma in a Turkish cohort. This is the first study that suggests pazopanib-induced hypothyroidism may act as a predictive marker for better outcomes in patients with advanced soft tissue sarcoma.

Keyphrases

metastatic renal cell carcinoma
type diabetes
drug induced
adipose tissue
metabolic syndrome
replacement therapy
endothelial cells
weight loss
smoking cessation